SG11201909160WA - Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same - Google Patents

Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same

Info

Publication number
SG11201909160WA
SG11201909160WA SG11201909160WA SG11201909160WA SG 11201909160W A SG11201909160W A SG 11201909160WA SG 11201909160W A SG11201909160W A SG 11201909160WA SG 11201909160W A SG11201909160W A SG 11201909160WA
Authority
SG
Singapore
Prior art keywords
binding
suite
inhibrx
jolla
domain
Prior art date
Application number
Inventor
Brendan P Eckelman
Michael D Kaplan
Katelyn M Willis
Quinn Deveraux
John C Timmer
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of SG11201909160WA publication Critical patent/SG11201909160WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Abstract

FIGUncleaved/Inactivated Cleaved/Activated Component #1 TAA-binding TAA-binding domain #1 domain #1 Linkers:protease t cleavage sites Anti-CD3-dsFv: Constrained —No Bindin TAA-binding TAR-binding domain #2 domain n v4f Component #2 Exposed Anti-CD3-dshi Region TAA-binding TAA-binding domain #1 domain #1 Component #1 Component #2 IgG-Fc Fc - tits (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) WI P0 I Iiiimmonimmonolomomummllonomovois (10) International Publication Number WO 2018/191438 Al PCT (51) International Patent Classification: C07K 16/28 (2006.01) C07K 16/46 (2006.01) (21) International Application Number: PCT/US2018/027195 (22) International Filing Date: 11 April 2018 (11.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/484,217 11 April 2017 (11.04.2017) US (71) Applicant: INHIBRX, INC. [US/US]; 11099 North Torrey Pines Road, Suite 280, La Jolla, California 92037 (US). (72) Inventors: ECKELMAN, Brendan P.; C/o Inhibrx LP, 11099 North Torrey Pines Road, Suite 280, La Jolla, Cali- fornia 92037 (US). KAPLAN, Michael D.; C/o Inhibrx LP, 11099 North Torrey Pines Road, Suite 280, La Jolla, Cali- fornia 92037 (US). WILLIS, Katelyn M.; C/o Inhibrx LP, 11099 North Torrey Pines Road, Suite 280, La Jolla, Cali- fornia 92037 (US). DEVERAUX, Quinn; C/o Inhibrx LP, 11099 North Torrey Pines Road, Suite 280, La Jolla, Cal- ifornia 92037 (US). TIMMER, John C.; C/o Inhibrx LP, 11099 North Torrey Pines Road, Suite 280, La Jolla, Cali- fornia 92037 (US). (74) Agent: POTTER, Karen et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (54) Title: MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME TM-binding TAR-binding domain #2 domain #2 (57) : The disclosure relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications. [Continued on next page] WO 2018/191438 Al IMEDIMOM0101011M1E130HHOMBEHMEMNIE UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201909160W 2017-04-11 2018-04-11 Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same SG11201909160WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762484217P 2017-04-11 2017-04-11
PCT/US2018/027195 WO2018191438A1 (en) 2017-04-11 2018-04-11 Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same

Publications (1)

Publication Number Publication Date
SG11201909160WA true SG11201909160WA (en) 2019-10-30

Family

ID=62092304

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909160W SG11201909160WA (en) 2017-04-11 2018-04-11 Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same

Country Status (15)

Country Link
US (2) US11866507B2 (en)
EP (1) EP3619235A1 (en)
JP (2) JP7164544B2 (en)
KR (1) KR20200005732A (en)
CN (1) CN110770255A (en)
AU (1) AU2018250641A1 (en)
BR (1) BR112019020940A2 (en)
CA (1) CA3058477A1 (en)
IL (1) IL269826A (en)
MX (1) MX2019012198A (en)
MY (1) MY200973A (en)
PH (1) PH12019502303A1 (en)
SG (1) SG11201909160WA (en)
TW (1) TW201843177A (en)
WO (1) WO2018191438A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180016618A (en) 2015-06-30 2018-02-14 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 BTLA fusion protein agonists and uses thereof
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
EP3619235A1 (en) * 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
BR112020004543A2 (en) 2017-09-08 2020-09-08 Maverick Therapeutics, Inc. conditionally restricted activated binding proteins
MX2020010638A (en) * 2018-04-11 2021-01-08 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses.
CN112789294A (en) * 2018-07-24 2021-05-11 印希比股份有限公司 Multispecific polypeptide constructs containing constrained CD3 binding domains and receptor binding regions and methods of use thereof
TW202021986A (en) * 2018-10-11 2020-06-16 美商英伊布里克斯公司 5t4 single domain antibodies and therapeutic compositions thereof
MX2021004496A (en) * 2018-10-22 2021-06-04 Univ Pittsburgh Commonwealth Sys Higher Education Cleavable activators of cxcr3 and methods of use.
US20230416385A1 (en) * 2018-11-01 2023-12-28 Shandong New Time Pharmaceutical Co., Ltd. Bispecific antibody and use thereof
CN111423512B (en) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 Multi-targeting fusion protein for blocking vascular endothelial cell growth and activating T cells and pharmaceutical composition comprising same
US20220098307A1 (en) * 2019-02-22 2022-03-31 Wuhan Yzy Biopharma Co., Ltd. Modified fc fragment, antibody comprising same, and application thereof
WO2020168555A1 (en) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 Cd3 antigen binding fragment and application thereof
CN114390938A (en) 2019-03-05 2022-04-22 武田药品工业有限公司 Constrained conditionally activated binding proteins
AU2020271100A1 (en) * 2019-04-12 2021-11-18 Sorrento Therapeutics, Inc. Activatable multi-specific antigen binding protein complexes
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
KR20220020879A (en) * 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. New IL-15 prodrugs and how to use them
EP3998083A4 (en) * 2019-07-12 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Anti-mutation type fgfr3 antibody and use therefor
KR20230015880A (en) * 2020-02-20 2023-01-31 윈 테라퓨틱스, 인크. Bispecific GD2 and B7H2 Binding Molecules and Methods of Use
WO2021173307A1 (en) * 2020-02-25 2021-09-02 Gensun Biopharma Inc. Trispecific t cell engagers
CN113321738A (en) * 2020-02-27 2021-08-31 启愈生物技术(上海)有限公司 Tumor-targeting, anti-CD 3 and T cell activation tri-functional fusion protein and application thereof
JP2023531672A (en) * 2020-06-30 2023-07-25 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド Binding proteins with H2L2 and HCAb structures
EP4178982A1 (en) * 2020-07-13 2023-05-17 Precirix N.V. Antibody fragment against folr1
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
WO2022042576A1 (en) * 2020-08-27 2022-03-03 盛禾(中国)生物制药有限公司 Multifunctional fusion protein and use thereof
CN112480267A (en) * 2020-12-04 2021-03-12 复旦大学附属华山医院 Promoter molecule capable of specifically recognizing endothelial cells in proliferation state and engineering cells
US11795227B2 (en) * 2021-03-24 2023-10-24 Shine-On Biomedical Co., Ltd. Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
CN117881413A (en) * 2021-06-30 2024-04-12 加利福尼亚大学董事会 Granzyme activatable membrane interaction peptides and methods of use
WO2023061417A1 (en) * 2021-10-12 2023-04-20 Concept To Medicine Biotech Co., Ltd. Cd3-targeting t-cell engagers with improved therapeutic index
WO2024064753A1 (en) * 2022-09-20 2024-03-28 Dana-Farber Cancer Institute, Inc. Reversible control of chimeric antigen receptor t cells

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
ATE255131T1 (en) 1991-06-14 2003-12-15 Genentech Inc HUMANIZED HEREGULIN ANTIBODIES
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE69830901T2 (en) 1997-05-02 2006-05-24 Genentech Inc., San Francisco A method for producing multispecific antibodies having heteromultimeric and common components
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
IL151853A0 (en) 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
CN1294148C (en) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 Single-stranded cyctic trispecific antibody
ME03330B (en) 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
ATE554107T1 (en) 2003-12-19 2012-05-15 Genentech Inc MONOVALENT ANTIBODIES FRAGMENTS SUITABLE AS THERAPEUTICS
CN100376599C (en) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 Recombining single chained three specific antibodies of anti CCA, anti CD 3, anti CD 28 through genetic engineering
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
NZ571208A (en) 2006-03-10 2011-12-22 Wyeth Corp Anti-5T4 antibodies and uses thereof
CA2694488A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
JP6035009B2 (en) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Activable binding polypeptides and methods for identification and use thereof
AU2016213702C1 (en) 2007-08-22 2018-11-29 Cytomx Therapeutics, Inc. Activatable binding polypeptides and methods of identification and use thereof
AU2013202755B2 (en) 2007-08-22 2016-05-12 Cytomx Therapeutics, Inc. Activatable binding polypeptides and methods of identification and use thereof
AU2008328779B2 (en) 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009068649A2 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
AU2015202560B2 (en) 2008-01-07 2017-06-15 Amgen Inc. Method for Making Antibody Fc-Heterodimeric Molecules Using Electrostatic Steering Effects
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN102056945A (en) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 Amino acid sequences directed against the Notch pathways and uses thereof
US20110097339A1 (en) 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
JP5675608B2 (en) 2008-07-18 2015-02-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Monovalent composition for CD28 binding and methods of use
BRPI1006141B8 (en) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc modified antibody compositions, methods of making and using the same
WO2010096838A2 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Llc Proproteins and methods of use thereof
CA2757669A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies
MX2011014008A (en) 2009-06-26 2012-06-01 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format.
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2609112B1 (en) 2010-08-24 2017-11-22 Roche Glycart AG Activatable bispecific antibodies
ES2758994T3 (en) 2010-11-05 2020-05-07 Zymeworks Inc Stable heterodimeric antibody design with mutations in the Fc domain
RS58765B1 (en) 2011-05-21 2019-06-28 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
AU2012311492A1 (en) 2011-09-23 2014-03-06 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5T4 and CD3
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
TWI476001B (en) 2011-12-26 2015-03-11 Ind Tech Res Inst Trimeric fc fusion and uses thereof
CA2861816C (en) * 2011-12-27 2022-11-08 Development Center For Biotechnology Light chain-bridged bispecific antibody
MX360772B (en) 2012-02-06 2018-11-15 Inhibrx Inc Cd47 antibodies and methods of use thereof.
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
JP2015528003A (en) 2012-07-13 2015-09-24 ザイムワークス，インコーポレイテッド Bispecific asymmetric heterodimer comprising anti-CD3 construct
CN104640561A (en) * 2012-07-23 2015-05-20 酵活有限公司 Immunoglobulin constructs comprising selective pairing of the light and heavy chains
CA2886036A1 (en) 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
CA2879768A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
AU2013337578C1 (en) 2012-11-02 2018-04-12 Zymeworks Inc. Crystal structures of heterodimeric Fc domains
US9951145B2 (en) 2012-11-27 2018-04-24 Ajou University Industry—Academic Cooperation Foundation CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
WO2014089113A1 (en) 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
BR112015013861A2 (en) 2012-12-18 2017-07-11 Novartis Ag long acting protein compositions and methods
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
MX368665B (en) 2013-03-15 2019-10-10 Abbvie Biotherapeutics Inc Fc variants.
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
RS63152B1 (en) 2013-07-25 2022-05-31 Cytomx Therapeutics Inc Multispecific antibodies, multispecific activatable antibodies and methods of using the same
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
RU2715232C2 (en) 2013-09-25 2020-02-26 Сайтомкс Терапьютикс, Инк. Substrates of matrix metalloproteinase and other cleavable moieties and methods for use thereof
CN106459153B (en) 2014-01-31 2021-12-21 西托姆克斯治疗公司 Substrates and other cleavable moieties for proteolytic enzymes and U-type plasminogen activators and methods of use thereof
EP3137496A4 (en) * 2014-05-02 2017-10-11 Emory University Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto
GB201411420D0 (en) 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
CA2952532A1 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
AU2015299163B2 (en) 2014-08-04 2019-07-18 F. Hoffmann-La Roche Ag Bispecific T cell activating antigen binding molecules
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
EP3186277B1 (en) 2014-08-27 2020-10-07 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
CA2959694C (en) 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
EP3197916A2 (en) 2014-09-25 2017-08-02 Amgen Inc. Protease-activatable bispecific proteins
US20170306044A1 (en) * 2014-10-09 2017-10-26 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
JP6696982B2 (en) * 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Heterodimeric antibodies that bind to CD3 and tumor antigens
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
ES2935274T3 (en) 2014-12-05 2023-03-03 Merck Patent Gmbh domain swapping antibody
KR102495820B1 (en) 2014-12-19 2023-02-06 치오메 바이오사이언스 가부시키가이샤 Fusion protein comprising three binding domains to 5t4 and cd3
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
RU2696378C2 (en) 2015-01-16 2019-08-01 Академиа Синика Molecular structures with targeting and effector elements
MA41374A (en) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF
JP7001474B2 (en) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド Non-immunogenic single domain antibody
CN114920848A (en) 2015-05-13 2022-08-19 埃博灵克斯股份有限公司 T cell recruitment polypeptides based on CD3 responsiveness
WO2016192613A1 (en) 2015-06-01 2016-12-08 中山大学 Bivalent antibody having single-domain antigen-binding fragment fused to conventional fab fragment
RS61062B1 (en) 2015-07-16 2020-12-31 Inhibrx Inc Multivalent and multispecific dr5-binding fusion proteins
IL257030B2 (en) 2015-07-23 2023-03-01 Inhibrx Inc Multivalent and multispecific gitr-binding fusion proteins, compositions comprising same and uses thereof
TW202346349A (en) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
KR20180038045A (en) 2015-08-17 2018-04-13 마크로제닉스, 인크. A bispecific monovalent diabody capable of binding to B7-H3 and CD3, and its use
WO2017055398A2 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
WO2017060144A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory tnf receptor
TW201722985A (en) 2015-11-02 2017-07-01 戊瑞治療有限公司 CD80 extracellular domain polypeptides and their use in cancer treatment
JP7328761B2 (en) 2016-01-11 2023-08-17 インヒブルクス インコーポレイテッド Multivalent multispecific OX40 binding fusion proteins
CN108779176A (en) 2016-01-11 2018-11-09 印希比股份有限公司 Multivalence and polyspecific 41BB combination fusion proteins
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
IL295538B2 (en) * 2016-04-13 2024-02-01 Vivia Biotech Sl Ex vivo bite-activated t cells
CA3021618A1 (en) 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018027025A1 (en) 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
CN108084265B (en) 2016-11-23 2021-07-02 复旦大学 Fully human single domain antibody specifically binding to human 5T4 antigen and application thereof
MA47200A (en) 2017-01-03 2019-11-13 Hoffmann La Roche BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING A 20H4.9 ANTI-4-1BB CLONE
US11427645B2 (en) 2017-03-15 2022-08-30 Oxford Biomedica (Uk) Limited 5T4-targeting agents and methods
MX2019011907A (en) 2017-04-04 2020-01-09 Hoffmann La Roche Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap.
EP3619235A1 (en) * 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
MX2020010638A (en) * 2018-04-11 2021-01-08 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses.
WO2019201866A1 (en) 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Fusion protein
CN112789294A (en) 2018-07-24 2021-05-11 印希比股份有限公司 Multispecific polypeptide constructs containing constrained CD3 binding domains and receptor binding regions and methods of use thereof
JP7453219B2 (en) 2018-10-11 2024-03-19 インヒブリックス， インコーポレイテッド PD-1 single domain antibodies and therapeutic compositions thereof
US20230124851A1 (en) 2018-10-11 2023-04-20 Inhibrx, lnc. B7h3 single domain antibodies and therapeutic compositions thereof
TW202028245A (en) 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3 single domain antibodies and therapeutic compositions thereof
TW202021986A (en) * 2018-10-11 2020-06-16 美商英伊布里克斯公司 5t4 single domain antibodies and therapeutic compositions thereof
KR20220148175A (en) 2020-01-29 2022-11-04 인히브릭스, 인크. CD28 single domain antibody and multivalent and multispecific constructs thereof

Also Published As

Publication number Publication date
RU2019135842A3 (en) 2022-01-25
US20240101704A1 (en) 2024-03-28
CN110770255A (en) 2020-02-07
EP3619235A1 (en) 2020-03-11
MX2019012198A (en) 2020-01-21
MY200973A (en) 2024-01-26
TW201843177A (en) 2018-12-16
BR112019020940A2 (en) 2020-05-05
IL269826A (en) 2019-11-28
US20190010242A1 (en) 2019-01-10
CA3058477A1 (en) 2018-10-18
US11866507B2 (en) 2024-01-09
WO2018191438A1 (en) 2018-10-18
JP7164544B2 (en) 2022-11-01
AU2018250641A1 (en) 2019-10-31
RU2019135842A (en) 2021-05-12
PH12019502303A1 (en) 2020-09-28
JP2023002686A (en) 2023-01-10
JP7450684B2 (en) 2024-03-15
NZ758264A (en) 2023-08-25
JP2020516287A (en) 2020-06-11
KR20200005732A (en) 2020-01-16

Similar Documents

Publication Publication Date Title
SG11201909160WA (en) Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201900138TA (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201906933SA (en) Functionalized erythroid cells
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201909395TA (en) Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201906468TA (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201809649WA (en) Macromolecule analysis employing nucleic acid encoding
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201909571SA (en) Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201809089QA (en) Bispecific binding proteins and uses thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201805906WA (en) Diagnostic and prognostic methods for cardiovascular diseases and events
SG11201906341XA (en) Improved serum albumin binders
SG11201407508RA (en) Encoding and decoding based on blending of sequences of samples along time
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201810757YA (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201809789SA (en) Dna monoclonal antibodies targeting checkpoint molecules
SG11201907048UA (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
SG11201908743SA (en) Methods and compositions for modulation of immune cells